Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
PIK3CA mutations in advanced cancers: characteristics and outcomes.
Janku F, Wheler JJ, Naing A, Stepanek VM, Falchook GS, Fu S, Garrido-Laguna I, Tsimberidou AM, Piha-Paul SA, Moulder SL, Lee JJ, Luthra R, Hong DS, Kurzrock R. Janku F, et al. Among authors: stepanek vm. Oncotarget. 2012 Dec;3(12):1566-75. doi: 10.18632/oncotarget.716. Oncotarget. 2012. PMID: 23248156 Free PMC article.
BRAF mutation testing with a rapid, fully integrated molecular diagnostics system.
Janku F, Claes B, Huang HJ, Falchook GS, Devogelaere B, Kockx M, Bempt IV, Reijans M, Naing A, Fu S, Piha-Paul SA, Hong DS, Holley VR, Tsimberidou AM, Stepanek VM, Patel SP, Kopetz ES, Subbiah V, Wheler JJ, Zinner RG, Karp DD, Luthra R, Roy-Chowdhuri S, Sablon E, Meric-Bernstam F, Maertens G, Kurzrock R. Janku F, et al. Among authors: stepanek vm. Oncotarget. 2015 Sep 29;6(29):26886-94. doi: 10.18632/oncotarget.4723. Oncotarget. 2015. PMID: 26330075 Free PMC article.
Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.
Ganesan P, Janku F, Naing A, Hong DS, Tsimberidou AM, Falchook GS, Wheler JJ, Piha-Paul SA, Fu S, Stepanek VM, Lee JJ, Luthra R, Overman MJ, Kopetz ES, Wolff RA, Kurzrock R. Ganesan P, et al. Among authors: stepanek vm. Mol Cancer Ther. 2013 Dec;12(12):2857-63. doi: 10.1158/1535-7163.MCT-13-0319-T. Epub 2013 Oct 3. Mol Cancer Ther. 2013. PMID: 24092809 Free PMC article.
Assessing PIK3CA and PTEN in early-phase trials with PI3K/AKT/mTOR inhibitors.
Janku F, Hong DS, Fu S, Piha-Paul SA, Naing A, Falchook GS, Tsimberidou AM, Stepanek VM, Moulder SL, Lee JJ, Luthra R, Zinner RG, Broaddus RR, Wheler JJ, Kurzrock R. Janku F, et al. Among authors: stepanek vm. Cell Rep. 2014 Jan 30;6(2):377-87. doi: 10.1016/j.celrep.2013.12.035. Epub 2014 Jan 16. Cell Rep. 2014. PMID: 24440717 Free PMC article. Clinical Trial.
Phase I Trial of Dabrafenib and Pazopanib in BRAF Mutated Advanced Malignancies.
Haraldsdottir S, Janku F, Poi M, Timmers C, Geyer S, Schaaf LJ, Sexton J, Wei L, Thurmond J, Velez-Bravo V, Stepanek VM, Bertino EM, Kendra K, Mortazavi A, Subbiah V, Phelps M, Shah MH. Haraldsdottir S, et al. Among authors: stepanek vm. JCO Precis Oncol. 2018 Nov;2:1-19. doi: 10.1200/PO.17.00247. JCO Precis Oncol. 2018. PMID: 35135123
12 results